Oncology supportive care: cross-border specialty drug access for international patients

Quick orientation

Supportive care needs affect essentially all patients undergoing systemic cancer therapy. Specific indications include chemotherapy-induced nausea and vomiting, neutropenia, anemia, mucositis, and cachexia.

Typical age of onset. Throughout cancer treatment.

Severity tiers. Severity tracks with intensity of cancer therapy and individual patient factors.

Why specialty drugs for Oncology supportive care are hard to access internationally

Newer FDA approvals for chemotherapy-induced neutropenia, post-transplant supportive care, and oral mucositis are not always registered internationally. Cross-border supply often supports patients undergoing high-intensity regimens.

Treatments approved by the FDA

• Udenyca (pegfilgrastim-cbqv) biosimilar — FDA approval: 2018. Mechanism: Recombinant G-CSF for chemotherapy-induced neutropenia. Route: Subcutaneous injection per cycle. US WAC ballpark: Approximately USD 3,000 to 5,000 per dose.
• Grafapex (treosulfan) — FDA approval: 2025. Mechanism: Conditioning agent for allogeneic stem cell transplant. Route: Intravenous infusion conditioning regimen. US WAC ballpark: Variable by protocol. Country pricing: UAE · Saudi Arabia · India · Egypt.
• Ryoncil (remestemcel-L-rknd) — FDA approval: 2024. Mechanism: Allogeneic mesenchymal stromal cell therapy for steroid-refractory acute pediatric GVHD. Route: Intravenous infusion twice weekly for 4 weeks. US WAC ballpark: Approximately USD 195,000 per course. Country pricing: Saudi Arabia · Qatar.
• Zegalogue (dasiglucagon) — FDA approval: 2021. Mechanism: Glucagon analog for severe hypoglycemia (relevant in some cancer-treatment-associated metabolic events). Route: Subcutaneous injection as needed. US WAC ballpark: Approximately USD 600 to 800 per dose. Country pricing: Saudi Arabia · India · Egypt.

Cross-border pathways used for Oncology supportive care

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Personal Import Scheme

What your physician needs to know

• Confirm specific supportive care need and indication.
• Document primary cancer treatment and concurrent therapy.
• Many supportive care drugs have specific timing requirements relative to chemotherapy.
• Coordinate with treating oncology team.
• Some products require specific administration conditions.

Common questions

What supportive care drugs does Reserve Meds support?

We focus on specialty products that are not broadly available locally, including newer G-CSF formulations, transplant supportive care, and indication-specific newer products.

Are biosimilars supported?

Yes, where FDA-approved and clinically appropriate.

How long does shipment take?

Five to ten business days for most supportive care drugs.

What documents are required?

Oncologist's prescription, treatment plan, and clinical summary.

Can these be added mid-cycle?

Generally yes, with appropriate clinical coordination.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Oncology supportive care, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Oncology supportive care

Reserved for you.